Cansino (688185.SH): MCV4 drug supplement application accepted

Zhitong Finance App News, Cansino (688185.SH) issued an announcement. The company's ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector) (“MCV4”) drug supplement application recently obtained a “Notice of Acceptance” issued by the State Drug Administration, acceptance number: CYSB2400306.

MCV4 Manhisin® is China's first meningococcal quadrivalent conjugate vaccine product. Its launch has narrowed the gap between China and developed countries in this field, filled the gap between China's lack of high-end vaccines in this field, and provided a better solution for preventing encephalitis in infants and young children in China. This supplementary application extends the age range of people applicable to MCV4 from “children aged 3 months to 3 months (47 months)” to “children aged 3 months to 6 years (83 months)”.